Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 403

1.

Development of Genome-Derived Tumor Type Prediction to Inform Clinical Cancer Care.

Penson A, Camacho N, Zheng Y, Varghese AM, Al-Ahmadie H, Razavi P, Chandarlapaty S, Vallejo CE, Vakiani E, Gilewski T, Rosenberg JE, Shady M, Tsui DWY, Reales DN, Abeshouse A, Syed A, Zehir A, Schultz N, Ladanyi M, Solit DB, Klimstra DS, Hyman DM, Taylor BS, Berger MF.

JAMA Oncol. 2019 Nov 14. doi: 10.1001/jamaoncol.2019.3985. [Epub ahead of print]

PMID:
31725847
2.

Co-Altered Ras/B-raf and TP53 is Associated with Extremes of Survivorship and Distinct Patterns of Metastasis in Metastatic Colorectal Cancer Patients.

Datta J, Smith JJ, Chatila WK, McAuliffe JC, Kandoth C, Vakiani E, Frankel TL, Ganesh K, Wasserman I, Lipsyc-Sharf M, Guillem J, Nash GM, Paty PB, Weiser MR, Saltz LB, Berger MF, Jarnagin WR, Balachandran V, Kingham TP, Kemeny NE, Cercek A, Garcia-Aguilar J, Taylor BS, Viale A, Yaeger R, Solit DB, Schultz N, D'Angelica MI.

Clin Cancer Res. 2019 Nov 12. pii: clincanres.2390.2019. doi: 10.1158/1078-0432.CCR-19-2390. [Epub ahead of print]

PMID:
31719050
3.

Genome-Wide Association Analyses of Equine Metabolic Syndrome Phenotypes in Welsh Ponies and Morgan Horses.

Norton E, Schultz N, Geor R, McFarlane D, Mickelson J, McCue M.

Genes (Basel). 2019 Nov 6;10(11). pii: E893. doi: 10.3390/genes10110893.

4.

Assessment of Hepatic Arterial Infusion of Floxuridine in Combination With Systemic Gemcitabine and Oxaliplatin in Patients With Unresectable Intrahepatic Cholangiocarcinoma: A Phase 2 Clinical Trial.

Cercek A, Boerner T, Tan BR, Chou JF, Gönen M, Boucher TM, Hauser HF, Do RKG, Lowery MA, Harding JJ, Varghese AM, Reidy-Lagunes D, Saltz L, Schultz N, Kingham TP, D'Angelica MI, DeMatteo RP, Drebin JA, Allen PJ, Balachandran VP, Lim KH, Sanchez-Vega F, Vachharajani N, Majella Doyle MB, Fields RC, Hawkins WG, Strasberg SM, Chapman WC, Diaz LA Jr, Kemeny NE, Jarnagin WR.

JAMA Oncol. 2019 Oct 31. doi: 10.1001/jamaoncol.2019.3718. [Epub ahead of print]

PMID:
31670750
5.

Adverse Events Associated with Cumulative Corticosteroid Use in Patients with Castration-Resistant Prostate Cancer: An Administrative Claims Analysis.

Schultz NM, Penson DF, Wilson S, Song Y, Yang H, Ramaswamy K, Lowentritt B.

Drug Saf. 2019 Oct 5. doi: 10.1007/s40264-019-00867-6. [Epub ahead of print]

PMID:
31587137
6.

Regorafenib in Combination with First-Line Chemotherapy for Metastatic Esophagogastric Cancer.

Moy RH, Dos Santos Fernandes G, Jonsson P, Chou JF, Basunia A, Ku GY, Chalasani SB, Boyar MS, Goldberg Z, Desai AM, Gabler A, Berger MF, Tang LH, Hechtman JF, Kelsen DP, Schattner M, Ilson DH, Solit DB, Taylor BS, Schultz N, Capanu M, Janjigian YY.

Oncologist. 2019 Sep 30. pii: theoncologist.2019-0492. doi: 10.1634/theoncologist.2019-0492. [Epub ahead of print]

PMID:
31570517
7.

Inclusion of herdmate data improves genomic prediction for milk-production and feed-efficiency traits within North American dairy herds.

Schultz NE, Weigel KA.

J Dairy Sci. 2019 Dec;102(12):11081-11091. doi: 10.3168/jds.2019-16820. Epub 2019 Sep 20.

8.

Lower dormancy with rapid germination is an important strategy for seeds in an arid zone with unpredictable rainfall.

Duncan C, Schultz N, Lewandrowski W, Good MK, Cook S.

PLoS One. 2019 Sep 10;14(9):e0218421. doi: 10.1371/journal.pone.0218421. eCollection 2019.

9.

Genomic stratification beyond Ras/B-Raf in colorectal liver metastasis patients treated with hepatic arterial infusion.

Smith JJ, Chatila WK, Sanchez-Vega F, Datta J, Connell LC, Szeglin BC, Basunia A, Boucher TM, Hauser H, Wasserman I, Wu C, Cercek A, Hechtman JF, Madden C, Jarnagin WR, Garcia-Aguilar J, D'Angelica MI, Yaeger R, Schultz N, Kemeny NE.

Cancer Med. 2019 Nov;8(15):6538-6548. doi: 10.1002/cam4.2415. Epub 2019 Sep 10.

10.

A Qualitative Investigation of Factors that Influence School Employee Health Behaviors: Implications for Wellness Programming.

Schultz NS, Chui KKH, Economos CD, Lichtenstein AH, Volpe SL, Sacheck JM.

J Sch Health. 2019 Nov;89(11):890-898. doi: 10.1111/josh.12831. Epub 2019 Sep 8.

11.

Genetic hallmarks of recurrent/metastatic adenoid cystic carcinoma.

Ho AS, Ochoa A, Jayakumaran G, Zehir A, Valero Mayor C, Tepe J, Makarov V, Dalin MG, He J, Bailey M, Montesion M, Ross JS, Miller VA, Chan L, Ganly I, Dogan S, Katabi N, Tsipouras P, Ha P, Agrawal N, Solit DB, Futreal PA, El Naggar AK, Reis-Filho JS, Weigelt B, Ho AL, Schultz N, Chan TA, Morris LG.

J Clin Invest. 2019 Oct 1;129(10):4276-4289. doi: 10.1172/JCI128227.

12.

Analysis of Tumor Genomic Pathway Alterations Using Broad-Panel Next-Generation Sequencing in Surgically Resected Lung Adenocarcinoma.

Zhou J, Sanchez-Vega F, Caso R, Tan KS, Brandt WS, Jones GD, Yan S, Adusumilli PS, Bott M, Huang J, Isbell JM, Sihag S, Molena D, Rusch VW, Chatila WK, Rekhtman N, Yang F, Ladanyi M, Solit DB, Berger MF, Schultz N, Jones DR.

Clin Cancer Res. 2019 Aug 27. doi: 10.1158/1078-0432.CCR-19-1651. [Epub ahead of print]

PMID:
31455678
13.

Chemical attributes of soil and growth of castor beans fertilized with drilling gravel from oil wells and castor pie.

Schultz N, Ouverney Leite T, de Andrade Martins Coelho L, Pinheiro Junior CR, Zonta E.

Sci Total Environ. 2019 Dec 10;695:133652. doi: 10.1016/j.scitotenv.2019.133652. Epub 2019 Aug 1.

PMID:
31425995
14.

Cancer-associated mutations in DICER1 RNase IIIa and IIIb domains exert similar effects on miRNA biogenesis.

Vedanayagam J, Chatila WK, Aksoy BA, Majumdar S, Skanderup AJ, Demir E, Schultz N, Sander C, Lai EC.

Nat Commun. 2019 Aug 15;10(1):3682. doi: 10.1038/s41467-019-11610-1.

15.

Multispectral imaging of hand eczema.

Hald M, Thyssen JP, Zachariae C, Røpke MA, Carstensen JM, Schultz N, Johansen JD.

Contact Dermatitis. 2019 Aug 6. doi: 10.1111/cod.13377. [Epub ahead of print]

PMID:
31389010
16.

Clinical and Molecular Predictors of Response to Immune Checkpoint Inhibitors in Patients with Advanced Esophagogastric Cancer.

Greally M, Chou JF, Chatila WK, Margolis M, Capanu M, Hechtman JF, Tuvy Y, Kundra R, Daian F, Ladanyi M, Kelsen DP, Ilson DH, Berger MF, Tang LH, Solit DB, Diaz LA Jr, Schultz N, Janjigian YY, Ku GY.

Clin Cancer Res. 2019 Oct 15;25(20):6160-6169. doi: 10.1158/1078-0432.CCR-18-3603. Epub 2019 Jul 23.

PMID:
31337644
17.

Exploration of Content and Reach of Physical Therapy-Related Discussion on Twitter.

Sabus C, Johns B, Schultz N, Gagnon K.

Phys Ther. 2019 Aug 1;99(8):1048-1055. doi: 10.1093/ptj/pzz063.

PMID:
31329985
18.

Integration and Analysis of CPTAC Proteomics Data in the Context of Cancer Genomics in the cBioPortal.

Wu P, Heins ZJ, Muller JT, Katsnelson L, de Bruijn I, Abeshouse AA, Schultz N, Fenyö D, Gao J.

Mol Cell Proteomics. 2019 Sep;18(9):1893-1898. doi: 10.1074/mcp.TIR119.001673. Epub 2019 Jul 15.

PMID:
31308250
19.

Tumour lineage shapes BRCA-mediated phenotypes.

Jonsson P, Bandlamudi C, Cheng ML, Srinivasan P, Chavan SS, Friedman ND, Rosen EY, Richards AL, Bouvier N, Selcuklu SD, Bielski CM, Abida W, Mandelker D, Birsoy O, Zhang L, Zehir A, Donoghue MTA, Baselga J, Offit K, Scher HI, O'Reilly EM, Stadler ZK, Schultz N, Socci ND, Viale A, Ladanyi M, Robson ME, Hyman DM, Berger MF, Solit DB, Taylor BS.

Nature. 2019 Jul;571(7766):576-579. doi: 10.1038/s41586-019-1382-1. Epub 2019 Jul 10.

PMID:
31292550
20.

Levels of islet amyloid polypeptide in cerebrospinal fluid and plasma from patients with Alzheimer's disease.

Schultz N, Janelidze S, Byman E, Minthon L, Nägga K, Hansson O, Wennström M.

PLoS One. 2019 Jun 17;14(6):e0218561. doi: 10.1371/journal.pone.0218561. eCollection 2019.

21.

Health Care Resource Utilization and Costs Associated with Corticosteroid Use in Patients with Castration-Resistant Prostate Cancer: An Administrative Claims Analysis.

Schultz NM, Penson DF, Wilson SD, Song Y, Yang H, Ramaswamy K, Lowentritt B.

J Manag Care Spec Pharm. 2019 Aug;25(8):889-897. doi: 10.18553/jmcp.2019.19109. Epub 2019 Jun 7.

22.

Publisher Correction: The long tail of oncogenic drivers in prostate cancer.

Armenia J, Wankowicz SAM, Liu D, Gao J, Kundra R, Reznik E, Chatila WK, Chakravarty D, Han GC, Coleman I, Montgomery B, Pritchard C, Morrissey C, Barbieri CE, Beltran H, Sboner A, Zafeiriou Z, Miranda S, Bielski CM, Penson AV, Tolonen C, Huang FW, Robinson D, Wu YM, Lonigro R, Garraway LA, Demichelis F, Kantoff PW, Taplin ME, Abida W, Taylor BS, Scher HI, Nelson PS, de Bono JS, Rubin MA, Sawyers CL, Chinnaiyan AM; PCF/SU2C International Prostate Cancer Dream Team, Schultz N, Van Allen EM.

Nat Genet. 2019 Jul;51(7):1194. doi: 10.1038/s41588-019-0451-6.

PMID:
31152158
23.

EGFR mutation subtypes and response to immune checkpoint blockade treatment in non-small cell lung cancer.

Hastings K, Yu H, Wei W, Sanchez-Vega F, DeVeaux M, Choi J, Rizvi H, Lisberg A, Truini A, Lydon CA, Liu Z, Henick BS, Wurtz A, Cai G, Plodkowski AJ, Long NM, Halpenny DF, Killam J, Oliva I, Schultz N, Riely GJ, Arcila ME, Ladanyi M, Zelterman D, Herbst RS, Goldberg SB, Awad MM, Garon EB, Gettinger S, Hellmann MD, Politi K.

Ann Oncol. 2019 May 14. pii: mdz141. doi: 10.1093/annonc/mdz141. [Epub ahead of print]

24.

Genomic correlates of clinical outcome in advanced prostate cancer.

Abida W, Cyrta J, Heller G, Prandi D, Armenia J, Coleman I, Cieslik M, Benelli M, Robinson D, Van Allen EM, Sboner A, Fedrizzi T, Mosquera JM, Robinson BD, De Sarkar N, Kunju LP, Tomlins S, Wu YM, Nava Rodrigues D, Loda M, Gopalan A, Reuter VE, Pritchard CC, Mateo J, Bianchini D, Miranda S, Carreira S, Rescigno P, Filipenko J, Vinson J, Montgomery RB, Beltran H, Heath EI, Scher HI, Kantoff PW, Taplin ME, Schultz N, deBono JS, Demichelis F, Nelson PS, Rubin MA, Chinnaiyan AM, Sawyers CL.

Proc Natl Acad Sci U S A. 2019 Jun 4;116(23):11428-11436. doi: 10.1073/pnas.1902651116. Epub 2019 May 6.

25.

Efficacy of Combined VEGFR1-3, PDGFα/β, and FGFR1-3 Blockade Using Nintedanib for Esophagogastric Cancer.

Won E, Basunia A, Chatila WK, Hechtman JF, Chou JF, Ku GY, Chalasani SB, Boyar MS, Goldberg Z, Desai AM, Tuvy Y, Berger MF, Tang L, Kelsen DP, Schattner M, Ilson DH, Capanu M, Solit DB, Schultz N, Janjigian YY.

Clin Cancer Res. 2019 Jul 1;25(13):3811-3817. doi: 10.1158/1078-0432.CCR-18-3789. Epub 2019 Apr 5.

PMID:
30952642
26.

Abnormal oxidative metabolism in a quiet genomic background underlies clear cell papillary renal cell carcinoma.

Xu J, Reznik E, Lee HJ, Gundem G, Jonsson P, Sarungbam J, Bialik A, Sanchez-Vega F, Creighton CJ, Hoekstra J, Zhang L, Sajjakulnukit P, Kremer D, Tolstyka Z, Casuscelli J, Stirdivant S, Tang J, Schultz N, Jeng P, Dong Y, Su W, Cheng EH, Russo P, Coleman JA, Papaemmanuil E, Chen YB, Reuter VE, Sander C, Kennedy SR, Hsieh JJ, Lyssiotis CA, Tickoo SK, Hakimi AA.

Elife. 2019 Apr 1;8. pii: e38986. doi: 10.7554/eLife.38986.

27.

The influence of rivaroxaban on markers of fibrinolysis and endothelial cell activation/injury in patients with venous thrombosis.

Schultz NH, Holme PA, Henriksson CE, Mowinckel MC, Sandset PM, Bratseth V, Jacobsen EM.

Thromb Res. 2019 May;177:154-156. doi: 10.1016/j.thromres.2019.03.010. Epub 2019 Mar 14. No abstract available.

PMID:
30903875
28.

The expanding landscape of 'oncohistone' mutations in human cancers.

Nacev BA, Feng L, Bagert JD, Lemiesz AE, Gao J, Soshnev AA, Kundra R, Schultz N, Muir TW, Allis CD.

Nature. 2019 Mar;567(7749):473-478. doi: 10.1038/s41586-019-1038-1. Epub 2019 Mar 20.

29.

Differential Role of Cannabis Use Motives in Predicting Impairment Across Three Measures.

Schultz NR, Bassett DT, Messina BG, Correia CJ.

J Stud Alcohol Drugs. 2019 Jan;80(1):26-31.

PMID:
30807271
30.

Evaluation of the psychometric properties of the cannabis use disorders identification test - revised among college students.

Schultz NR, Bassett DT, Messina BG, Correia CJ.

Addict Behav. 2019 Aug;95:11-15. doi: 10.1016/j.addbeh.2019.02.016. Epub 2019 Feb 18.

PMID:
30798191
31.

A Potential Role for α-Amylase in Amyloid-β-Induced Astrocytic Glycogenolysis and Activation.

Byman E, Schultz N; Netherlands Brain Bank, Blom AM, Wennström M.

J Alzheimers Dis. 2019;68(1):205-217. doi: 10.3233/JAD-180997.

PMID:
30775997
32.

Evaluation of an HMGA2 variant for pleiotropic effects on height and metabolic traits in ponies.

Norton EM, Avila F, Schultz NE, Mickelson JR, Geor RJ, McCue ME.

J Vet Intern Med. 2019 Mar;33(2):942-952. doi: 10.1111/jvim.15403. Epub 2019 Jan 21.

33.

American Association for Cancer Research Project Genomics Evidence Neoplasia Information Exchange: From Inception to First Data Release and Beyond-Lessons Learned and Member Institutions' Perspectives.

Micheel CM, Sweeney SM, LeNoue-Newton ML, André F, Bedard PL, Guinney J, Meijer GA, Rollins BJ, Sawyers CL, Schultz N, Shaw KRM, Velculescu VE, Levy MA; AACR Project GENIE Consortium.

JCO Clin Cancer Inform. 2018 Dec;2:1-14. doi: 10.1200/CCI.17.00083. Review.

34.

Analysis of the Prevalence of Microsatellite Instability in Prostate Cancer and Response to Immune Checkpoint Blockade.

Abida W, Cheng ML, Armenia J, Middha S, Autio KA, Vargas HA, Rathkopf D, Morris MJ, Danila DC, Slovin SF, Carbone E, Barnett ES, Hullings M, Hechtman JF, Zehir A, Shia J, Jonsson P, Stadler ZK, Srinivasan P, Laudone VP, Reuter V, Wolchok JD, Socci ND, Taylor BS, Berger MF, Kantoff PW, Sawyers CL, Schultz N, Solit DB, Gopalan A, Scher HI.

JAMA Oncol. 2019 Apr 1;5(4):471-478. doi: 10.1001/jamaoncol.2018.5801.

PMID:
30589920
35.

Statin treatment before stroke reduces pro-inflammatory cytokine levels after stroke.

Schultz NEØ, Hasseldam H, Rasmussen RS, Vindegaard N, McWilliam O, Iversen HK, Johansen FF.

Neurol Res. 2019 Apr;41(4):289-297. doi: 10.1080/01616412.2018.1558000. Epub 2018 Dec 21.

PMID:
30574850
36.

The impact of rivaroxaban on primary hemostasis in patients with venous thrombosis.

Schultz NH, Holme PA, Bjørnsen S, Henriksson CE, Sandset PM, Jacobsen EM.

Platelets. 2018 Dec 20:1-5. doi: 10.1080/09537104.2018.1557618. [Epub ahead of print]

PMID:
30569801
37.

Loss of the FAT1 Tumor Suppressor Promotes Resistance to CDK4/6 Inhibitors via the Hippo Pathway.

Li Z, Razavi P, Li Q, Toy W, Liu B, Ping C, Hsieh W, Sanchez-Vega F, Brown DN, Da Cruz Paula AF, Morris L, Selenica P, Eichenberger E, Shen R, Schultz N, Rosen N, Scaltriti M, Brogi E, Baselga J, Reis-Filho JS, Chandarlapaty S.

Cancer Cell. 2018 Dec 10;34(6):893-905.e8. doi: 10.1016/j.ccell.2018.11.006.

PMID:
30537512
38.

The Juvenile Mental Health Advocacy Project for Court-Involved Youths.

Elliott P, Schultz N, Feinberg E.

Psychiatr Serv. 2018 Dec 1;69(12):1268. doi: 10.1176/appi.ps.691201. No abstract available.

PMID:
30501492
39.

Synchronous and metachronous liver metastases in patients with colorectal cancer.

Okholm C, Mollerup TK, Schultz NA, Strandby RB, Achiam MP.

Dan Med J. 2018 Dec;65(12). pii: A5524.

PMID:
30511638
40.

Associations between endocrine disrupting chemicals and equine metabolic syndrome phenotypes.

Durward-Akhurst SA, Schultz NE, Norton EM, Rendahl AK, Besselink H, Behnisch PA, Brouwer A, Geor RJ, Mickelson JR, McCue ME.

Chemosphere. 2019 Mar;218:652-661. doi: 10.1016/j.chemosphere.2018.11.136. Epub 2018 Nov 26.

PMID:
30502704
41.

Heritability of metabolic traits associated with equine metabolic syndrome in Welsh ponies and Morgan horses.

Norton EM, Schultz NE, Rendahl AK, Mcfarlane D, Geor RJ, Mickelson JR, McCue ME.

Equine Vet J. 2019 Jul;51(4):475-480. doi: 10.1111/evj.13053. Epub 2018 Dec 15.

PMID:
30472742
42.

Future Liver Remnant (FLR) Increase in Patients with Colorectal Liver Metastases Is Highest the First Week After Portal Vein Occlusion : FLR Increase in Patients with CRLM Is Highest the First Week After PVO.

Hasselgren K, Sandström P, Røsok BI, Sparrelid E, Lindell G, Larsen PN, Larsson AL, Schultz NA, Björnbeth BA, Isaksson B, Rizell M, Björnsson B.

J Gastrointest Surg. 2019 Mar;23(3):556-562. doi: 10.1007/s11605-018-4031-3. Epub 2018 Nov 21.

43.

EGFR and MET Amplifications Determine Response to HER2 Inhibition in ERBB2-Amplified Esophagogastric Cancer.

Sanchez-Vega F, Hechtman JF, Castel P, Ku GY, Tuvy Y, Won H, Fong CJ, Bouvier N, Nanjangud GJ, Soong J, Vakiani E, Schattner M, Kelsen DP, Lefkowitz RA, Brown K, Lacouture ME, Capanu M, Mattar M, Qeriqi B, Cecchi F, Tian Y, Hembrough T, Nagy RJ, Lanman RB, Larson SM, Pandit-Taskar N, Schöder H, Iacobuzio-Donahue CA, Ilson DH, Weber WA, Berger MF, de Stanchina E, Taylor BS, Lewis JS, Solit DB, Carrasquillo JA, Scaltriti M, Schultz N, Janjigian YY.

Cancer Discov. 2019 Feb;9(2):199-209. doi: 10.1158/2159-8290.CD-18-0598. Epub 2018 Nov 21.

PMID:
30463996
44.

Immunogenomic analyses associate immunological alterations with mismatch repair defects in prostate cancer.

Rodrigues DN, Rescigno P, Liu D, Yuan W, Carreira S, Lambros MB, Seed G, Mateo J, Riisnaes R, Mullane S, Margolis C, Miao D, Miranda S, Dolling D, Clarke M, Bertan C, Crespo M, Boysen G, Ferreira A, Sharp A, Figueiredo I, Keliher D, Aldubayan S, Burke KP, Sumanasuriya S, Fontes MS, Bianchini D, Zafeiriou Z, Mendes LST, Mouw K, Schweizer MT, Pritchard CC, Salipante S, Taplin ME, Beltran H, Rubin MA, Cieslik M, Robinson D, Heath E, Schultz N, Armenia J, Abida W, Scher H, Lord C, D'Andrea A, Sawyers CL, Chinnaiyan AM, Alimonti A, Nelson PS, Drake CG, Van Allen EM, de Bono JS.

J Clin Invest. 2018 Nov 1;128(11):5185. doi: 10.1172/JCI125184. Epub 2018 Nov 1. No abstract available.

45.

Change in dominance determines herbivore effects on plant biodiversity.

Koerner SE, Smith MD, Burkepile DE, Hanan NP, Avolio ML, Collins SL, Knapp AK, Lemoine NP, Forrestel EJ, Eby S, Thompson DI, Aguado-Santacruz GA, Anderson JP, Anderson TM, Angassa A, Bagchi S, Bakker ES, Bastin G, Baur LE, Beard KH, Beever EA, Bohlen PJ, Boughton EH, Canestro D, Cesa A, Chaneton E, Cheng J, D'Antonio CM, Deleglise C, Dembélé F, Dorrough J, Eldridge DJ, Fernandez-Going B, Fernández-Lugo S, Fraser LH, Freedman B, García-Salgado G, Goheen JR, Guo L, Husheer S, Karembé M, Knops JMH, Kraaij T, Kulmatiski A, Kytöviita MM, Lezama F, Loucougaray G, Loydi A, Milchunas DG, Milton SJ, Morgan JW, Moxham C, Nehring KC, Olff H, Palmer TM, Rebollo S, Riginos C, Risch AC, Rueda M, Sankaran M, Sasaki T, Schoenecker KA, Schultz NL, Schütz M, Schwabe A, Siebert F, Smit C, Stahlheber KA, Storm C, Strong DJ, Su J, Tiruvaimozhi YV, Tyler C, Val J, Vandegehuchte ML, Veblen KE, Vermeire LT, Ward D, Wu J, Young TP, Yu Q, Zelikova TJ.

Nat Ecol Evol. 2018 Dec;2(12):1925-1932. doi: 10.1038/s41559-018-0696-y. Epub 2018 Oct 29.

46.

Prospective Genotyping of Hepatocellular Carcinoma: Clinical Implications of Next-Generation Sequencing for Matching Patients to Targeted and Immune Therapies.

Harding JJ, Nandakumar S, Armenia J, Khalil DN, Albano M, Ly M, Shia J, Hechtman JF, Kundra R, El Dika I, Do RK, Sun Y, Kingham TP, D'Angelica MI, Berger MF, Hyman DM, Jarnagin W, Klimstra DS, Janjigian YY, Solit DB, Schultz N, Abou-Alfa GK.

Clin Cancer Res. 2019 Apr 1;25(7):2116-2126. doi: 10.1158/1078-0432.CCR-18-2293. Epub 2018 Oct 29.

PMID:
30373752
47.

Genetic and Epigenetic Determinants of Aggressiveness in Cribriform Carcinoma of the Prostate.

Elfandy H, Armenia J, Pederzoli F, Pullman E, Pertega-Gomes N, Schultz N, Viswanathan K, Vosoughi A, Blattner M, Stopsack KH, Zadra G, Penney KL, Mosquera JM, Tyekucheva S, Mucci LA, Barbieri C, Loda M.

Mol Cancer Res. 2019 Feb;17(2):446-456. doi: 10.1158/1541-7786.MCR-18-0440. Epub 2018 Oct 17.

PMID:
30333152
48.

FOLFCIS Treatment and Genomic Correlates of Response in Advanced Anal Squamous Cell Cancer.

Mondaca S, Chatila WK, Bates D, Hechtman JF, Cercek A, Segal NH, Stadler ZK, Varghese AM, Kundra R, Capanu M, Shia J, Schultz N, Saltz L, Yaeger R.

Clin Colorectal Cancer. 2019 Mar;18(1):e39-e52. doi: 10.1016/j.clcc.2018.09.005. Epub 2018 Sep 21.

49.

Genomic Differences Between "Primary" and "Secondary" Muscle-invasive Bladder Cancer as a Basis for Disparate Outcomes to Cisplatin-based Neoadjuvant Chemotherapy.

Pietzak EJ, Zabor EC, Bagrodia A, Armenia J, Hu W, Zehir A, Funt S, Audenet F, Barron D, Maamouri N, Li Q, Teo MY, Arcila ME, Berger MF, Schultz N, Dalbagni G, Herr HW, Bajorin DF, Rosenberg JE, Al-Ahmadie H, Bochner BH, Solit DB, Iyer G.

Eur Urol. 2019 Feb;75(2):231-239. doi: 10.1016/j.eururo.2018.09.002. Epub 2018 Oct 2.

PMID:
30290956
50.

Correction to: Number-needed-to-treat analysis of clinical progression in patients with metastatic castration-resistant prostate cancer in the STRIVE and TERRAIN trials.

Schultz NM, Shore ND, Chowdhury S, Klotz LH, Concepcion RS, Penson DF, Karsh LI, Yang H, Brown BA, Barlev A, Flanders SC.

BMC Urol. 2018 Oct 1;18(1):84. doi: 10.1186/s12894-018-0397-5.

Supplemental Content

Loading ...
Support Center